EquitySectoral/ ThematicDirectGrowthVery High

Invesco India Pharma and Healthcare Fund

Q: What is the NAV of Invesco India Pharma and Healthcare Fund?

As of 11 Sep 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹9.99 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has Invesco India Pharma and Healthcare Fund delivered?

Invesco India Pharma and Healthcare Fund has returned -0.30% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund charges an expense ratio of 0.59% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: How risky is Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is rated very high on SEBI's risk-o-meter and its worst peak-to-trough fall in our sample was -0.3%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What is the benchmark of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare Total Return Index. Its alpha and beta on this page are measured against that index.

Q: Who manages Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.

Q: How is Invesco India Pharma and Healthcare Fund taxed?

Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

Invesco Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV

₹9.99

-0.30% 1D

as of 11 Sep 2026

About this plan

This is the Direct plan of Invesco India Pharma and Healthcare Fund — bought from the fund house, with no distributor commission in its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.

Compare SIP calculator

Performance

-0.30%absolute

52-week rangePrev NAV ₹10.02

Latest ₹9.99

Low ₹9.990th percentile of its 52-week rangeHigh ₹10.02

Scorecard

Not rated

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. Not rated — this fund has no full year of NAV history yet. A rating needs at least a 1-year return to rank its performance against peers.

Performance—

Not enough Sectoral/ Thematic peers to rank yet

Risk—

Volatility not available yet

CostLow

0.6% expense vs 1.3% category avg

Consistency—

Not enough history for a rolling 3Y view

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

Low expense ratio (0.59%) vs the Sectoral/ Thematic average of 1.25%

Concerns

No significant concerns identified.

Key Metrics

Annual fee charged by the fund, already deducted from NAV

Category 1.25%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

Category 29.37

Excess return per unit of total volatility (rf = 6.5%)

—

Category 0.33

Scheme Info

Definitions

Plan

Direct · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

Exit Load

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Smallest recurring SIP instalment the scheme accepts

Smallest one-time (lumpsum) investment the scheme accepts

Benchmark

Start of our NAV history for this plan. Direct plans begin 1 Jan 2013, so this is the plan's inception — not necessarily the scheme's original launch date.

10 Sep 2026

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

—

Absolute return over the last 3 months (not annualized)

—

Absolute return over the last 6 months (not annualized)

—

Absolute return since 1 Jan of this year (not annualized)

-0.30%

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

—

3-year annualized return (CAGR)

—

5-year annualized return (CAGR)

—

10-year annualized return (CAGR)

—

Annualized return (CAGR) since the fund's inception

-0.30%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

—

Excess return per unit of total volatility (rf = 6.5%)

—

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

—

Largest peak-to-trough decline over full history

-0.30%

Benchmark ratios (vs Nifty 500 · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty 500

—

Sensitivity to Nifty 500 moves; 1 = moves with the index

—

How much of the fund's movement Nifty 500 explains

—

Excess return per unit of beta (market risk)

—

Active return over the benchmark per unit of tracking error

—

Annualized std dev of fund-minus-benchmark returns

—

Fund's share of benchmark gains in up months (100 = matches index)

—

Fund's share of benchmark losses in down months (lower is better)

—

Computed vs the Nifty 500 price index — the closest match to this fund's mandate. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹10.00K

Current value

₹10.00K

Absolute

0.00%

XIRR

+450.01%

Value vs. invested

ValueInvested

Pick a longer period to plot the path.

1 monthly installments of ₹10,000 into Invesco India Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

History points

Expense ratio

0.59%

AUM

—

Portfolio turnover

—

Exit load

Exit load of 0.50%, if redeemed within 3 months.

Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Sectoral/ Thematic

Compare all


Invesco India Pharma and Healthcare FundThis fund Invesco · Direct · Growth	—	—	—	—	—	0.59%	—
Nippon India Taiwan Equity Fund Nippon India · Direct · Growth	★★★★☆	+114.25%	+60.64%	—	—	1.06%	₹1,110Cr
HDFC Defence Fund HDFC · Direct · Growth	★★★★☆	+31.47%	+36.16%	—	65.67	0.89%	₹9,371Cr
HDFC Transportation and Logistics Fund HDFC · Direct · Growth	★★★★☆	+9.75%	+24.93%	—	37.19	1.09%	₹1,685Cr
SBI Healthcare Opportunities Fund SBI · Direct · Growth	★★★★★	+21.41%	+24.24%	+18.66%	55.39	1.03%	₹4,319Cr
UTI - Healthcare Fund UTI · Direct · Growth	★★★★☆	+16.47%	+24.12%	+16.20%	42.24	1.33%	₹1,181Cr

Invesco in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of Invesco India Pharma and Healthcare Fund?

As of 11 Sep 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹9.99 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Invesco India Pharma and Healthcare Fund delivered?

Invesco India Pharma and Healthcare Fund has returned -0.30% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund charges an expense ratio of 0.59% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

How risky is Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is rated very high on SEBI's risk-o-meter and its worst peak-to-trough fall in our sample was -0.3%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What is the benchmark of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare Total Return Index. Its alpha and beta on this page are measured against that index.

Who manages Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.

How is Invesco India Pharma and Healthcare Fund taxed?

Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.